Fischer Seth H. Z. 4

What Happened

• Seth H. Z. Fischer, a director of Milestone Pharmaceuticals, was granted a derivative award for 77,000 shares (transaction coded A) on June 10, 2026. The reported acquisition price is $0 per share (total reported value $0), indicating a grant/award rather than an open‑market purchase.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (timely within the usual 2‑business‑day window).
• Securities: 77,000 derivative shares granted at $0.00 per share.
• Shares owned after transaction: Not specified in the provided filing details.
• Vesting: The award vests in 12 equal monthly installments beginning July 10, 2026; however, the award will in any case be fully vested on the date of the next annual meeting of stockholders, subject to Fischer’s continued service (footnote F1).
• Transaction type: Grant/award (not a purchase, sale, or exercise); no immediate cashless sale or exercise reported.

Context

• This is a compensation grant to a director (a routine corporate governance/compensation event) and does not represent an open‑market purchase or sale. Derivative awards typically convert to ordinary shares only as they vest and according to the plan’s terms. The filing appears timely and contains vesting acceleration tied to the next annual meeting; no additional behavioral or trading plan (e.g., 10b5‑1) was disclosed in the provided details.